{"id":"placebo-palonosetron-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1189679","moleculeType":"Small molecule","molecularWeight":"296.41"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Palonosetron blocks serotonin receptors (5-HT3) in the chemoreceptor trigger zone and gastrointestinal tract to prevent acute nausea and vomiting. Dexamethasone, a glucocorticoid, provides additional antiemetic effects through multiple mechanisms including suppression of inflammatory mediators and enhancement of 5-HT3 antagonist efficacy, particularly for delayed emesis. The combination addresses both acute and delayed chemotherapy-induced nausea and vomiting (CINV).","oneSentence":"This is a combination regimen using palonosetron (a 5-HT3 antagonist) and dexamethasone (a corticosteroid) to prevent chemotherapy-induced nausea and vomiting, with placebo as a control arm.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:18.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT06554184","phase":"PHASE3","title":"HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-09-03","conditions":"Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents","enrollment":706},{"nctId":"NCT03367572","phase":"PHASE3","title":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Rochester NCORP Research Base","startDate":"2018-04-19","conditions":"Breast Carcinoma","enrollment":1363},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT06766825","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-02-07","conditions":"Post COVID-19 Condition, Long COVID Syndrome, Persistent COVID-19","enrollment":90},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT00553059","phase":"PHASE3","title":"Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":62},{"nctId":"NCT02203253","phase":"PHASE3","title":"Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting","status":"COMPLETED","sponsor":"China Medical University, China","startDate":"2014-07","conditions":"Neoplasms","enrollment":642},{"nctId":"NCT00475085","phase":"PHASE3","title":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Joseph Roscoe","startDate":"2006-12","conditions":"Nausea","enrollment":1021},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT00952133","phase":"PHASE4","title":"Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-07","conditions":"PONV","enrollment":118},{"nctId":"NCT02400866","phase":"PHASE2","title":"A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy","status":"UNKNOWN","sponsor":"Korean South West Oncology Group","startDate":"2015-05","conditions":"Cancer","enrollment":58},{"nctId":"NCT01088022","phase":"PHASE3","title":"Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Perugia","startDate":"2010-04","conditions":"Nausea, Vomiting","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo, Palonosetron, Dexamethasone","genericName":"Placebo, Palonosetron, Dexamethasone","companyName":"Azienda Ospedaliera di Perugia","companyId":"azienda-ospedaliera-di-perugia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination regimen using palonosetron (a 5-HT3 antagonist) and dexamethasone (a corticosteroid) to prevent chemotherapy-induced nausea and vomiting, with placebo as a control arm. Used for Prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}